# US 2023/0406814 A2 · Novel aromatic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406814 A2
- Document ID: US20230406814A2
- Status: Published application
- Kind: A2
- Application number: 18/064,576
- Filed: 2022-12-12
- Published: 2023-12-21
- Earliest claimed: 2017-02-24
- Assignees: XENIOPRO GmbH
- Applicants: Xeniopro GmbH
- Inventors: Viktoria REINMÜLLER
- Web page: https://patentgrep.com/patent/US20230406814A2

## CPC

- A61P 35/00: Antineoplastic agents
- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- C07C 65/24: polycyclic
- C07C 69/94: of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- C07D 213/80: in position 3
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.

## Claims

### Claim 1

A compound selected from the group consisting of:
(i) a compound of formula I,
wherein X is CH or N,
R1═C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C4-C12 bicycloalkyl, C6-C12 bicycloalkenyl, C5-C14 tricycloalkyl,
wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues can be perhalogenated;
R2═H, C1-C6 alkyl, C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
or a salt or solvate thereof,
(ii) a compound of formula II,
wherein X and R1 are defined as in formula I,
R3═H, C1-C6 alkyl, or C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
R4═C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated,
or a salt or solvate thereof,
wherein when R4 is C1-C6 alkyl, the alkyl residues can be linear or branched, and are substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
(iii) a compound of formula III,
wherein X, R1 and R2 are defined as in formula I,
or a salt or solvate thereof,
(iv) a compound of formula IV,
wherein X and R1 are defined as in formula I,
R3 is defined as in formula II,
R4═H, C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated,
or a salt or solvate thereof,
or a salt or solvate thereof,
(v) a compound of formula V,
wherein n=0-5, which comprises cyclopropyl (n=0), cyclobutyl (n=1), cyclopentyl (n=2), cyclohexyl (n=3), cycloheptyl (n=4) and cyclooctyl (n=5),
wherein the said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein the said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups can be perhalogenated;
R5═C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl,
wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and are perhalogenated,
and wherein all cycloalkyl and cycloalkenyl residues are perhalogenated,
or wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and OC1-C3 alkyl optionally halogenated or perhalogenated,
and wherein all cycloalkyl and cycloalkenyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
R6-R9 are independently from each other selected from —H, —F, —Cl, —Br, —I, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, C2-C4 alkynyl, C3-C5 cycloalkyl, and wherein all alkyl, alkenyl, alkynyl and cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
Y=a six-membered aromatic ring selected from benzene, pyridine, pyrimidine, pyridazine or pyrazine;
wherein the benzene ring is not substituted, or it is substituted with one to four of the substituents independently selected from R10-R13,
and wherein the pyridine ring is not substituted, or it is substituted at the carbon positions with one to three of the substituents independently selected from R10-R12, and wherein the N-atom of the pyridine ring may be in ortho-position relative to the ether bond,
and wherein the pyrimidine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein the N-atoms of the pyrimidine ring may be in ortho-position relative to the ether bond,
and wherein the pyridazine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein an N-atom of the pyridazine ring may be in ortho-position relative to the ether bond,
and wherein the pyrazine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein an N-atom of the pyrazine ring may be in ortho-position relative to the ether bond,
R10-R13 are independently from each other selected from —F, —Cl, —Br, —I, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, C2-C4 alkynyl, C3-C5 cycloalkyl, and wherein all alkyl, alkenyl, alkynyl and cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
Z═O or S,
R14═OR2 or NR3R4
wherein R2 is defined as in formula I,
and wherein R3═H, C1-C6 alkyl, or C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
and wherein R4═H, C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated,
and a salt or solvate thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein in the compound of Formula I, II, III and IV, R1 is selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, iso-propyl, tert-butyl, tert-pentyl, 3-pentyl, —CF3, —CF2CF3, —(CF2)2CF3, —(CF2)3CF3, —CH(CF3)2, —CF(CF3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, bicyclo[2.2.2]octyl, adamantyl, and 9-methylbicyclo[3.3.1]nonyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein in the compound of Formula I, III and V, R2 is selected from the group consisting of H, methyl and ethyl wherein said methyl and ethyl is optionally fluorinated or perfluorinated.

### Claim 4 (depends on 1)

The compound of claim 1, wherein in the compound of Formula II, IV and V, R3 is H or methyl, wherein said methyl is optionally fluorinated or perfluorinated.

### Claim 5 (depends on 1)

The compound of claim 1, wherein in the compound of Formula II, IV and V, R4 is selected from the group consisting of OH and methyl wherein in the case of Formula II and IV said methyl is fluorinated or perfluorinated and wherein in the case of Formula V said methyl is optionally fluorinated or perfluorinated.

### Claim 6 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, n is 0 as constituting cyclopropyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein said cyclopropyl is unsubstituted.

### Claim 8 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, R5 is a perfluorinated alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl residue.

### Claim 9 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, R5 is —CF3 or —CF2CF3.

### Claim 10 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, R6-R8 are H and R9 is selected from the group consisting of —H, —F, —Cl or —CH3.

### Claim 11 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, Y=benzene or pyridine being not substituted with any of the residues selected from R10-R13, or being substituted with one of the substituents selected from R10-R13 being —F at the carbon atom in ortho-position relative to the ether bond.

### Claim 12 (depends on 1)

The compound of claim 1, wherein in the compound of Formula V, Z═O.

### Claim 13 (depends on 1)

The compound of claim 1, wherein all alkyl residues of R4 can be linear or branched, and are substituted with one or more substituents independently selected from the group consisting of —F, —Cl, —Br, —I; OC1-C3 alkyl and halogenated C1-C3 alkyl.

### Claim 14 (depends on 13)

The compound according to claim 13, wherein said C1-C3 alkyl is perhalogenated, and said OC1-C3 alkyl is halogenated or perhalogenated.

### Claim 15

A pharmaceutical composition, comprising
a) an active agent selected from the group consisting of
(i) a compound of formula I,
wherein X is CH or N,
R1═C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C4-C12 bicycloalkyl, C6-C12 bicycloalkenyl, C5-C14 tricycloalkyl,
wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues can be perhalogenated;
R2═H, C1-C6 alkyl, C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
or a salt or solvate thereof,
(ii) a compound of formula II,
wherein X and R1 are defined as in formula I,
R3═H, C1-C6 alkyl, or C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
R4═C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
or a salt or solvate thereof,
wherein when R4 is C1-C6 alkyl, the alkyl residues can be linear or branched, and are substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
(iii) a compound of formula III,
wherein X, R1 and R2 are defined as in formula I,
or a salt or solvate thereof,
(iv) a compound of formula IV,
wherein X and R1 are defined as in formula I,
R3 is defined as in formula II, and
R4═H, C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl
optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated,
or a salt or solvate thereof,
(v) a compound of formula V,
wherein n=0-5, which comprises cyclopropyl (n=0), cyclobutyl (n=1), cyclopentyl (n=2), cyclohexyl (n=3), cycloheptyl (n=4) and cyclooctyl (n=5),
wherein the said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein the said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups can be perhalogenated;
R5═C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl,
wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and are perhalogenated,
and wherein all cycloalkyl and cycloalkenyl residues are perhalogenated,
or wherein all alkyl, alkenyl and alkynyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and OC1-C3 alkyl optionally halogenated or perhalogenated,
and wherein all cycloalkyl and cycloalkenyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I, —CN, —NCO, —NCS; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
R6-R9 are independently from each other selected from —H, —F, —Cl, —Br, —I, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, C2-C4 alkynyl, C3-C5 cycloalkyl, and wherein all alkyl, alkenyl, alkynyl and cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
Y=a six-membered aromatic ring selected from benzene, pyridine, pyrimidine, pyridazine or pyrazine;
wherein the benzene ring is not substituted, or it is substituted with one to four of the substituents independently selected from R10-R13,
and wherein the pyridine ring is not substituted, or it is substituted at the carbon positions with one to three of the substituents independently selected from R10-R12, and wherein the N-atom of the pyridine ring may be in ortho-position relative to the ether bond,
and wherein the pyrimidine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein the N-atoms of the pyrimidine ring may be in ortho-position relative to the ether bond,
and wherein the pyridazine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein an N-atom of the pyridazine ring may be in ortho-position relative to the ether bond,
and wherein the pyrazine ring is not substituted, or it is substituted at the carbon positions with one or two of the substituents independently selected from R10-R11, and wherein an N-atom of the pyrazine ring may be in ortho-position relative to the ether bond,
R10-R13 are independently from each other selected from —F, —Cl, —Br, —I, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, C2-C4 alkynyl, C3-C5 cycloalkyl, and wherein all alkyl, alkenyl, alkynyl and cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
Z═O or S,
R14═OR2 or NR3R4
wherein R2 is defined as in formula I,
and wherein R3═H, C1-C6 alkyl, or C3-C6 cycloalkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated, and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
and wherein R4═H, C1-C6 alkyl, C3-C6 cycloalkyl, OH or OC1-C6 alkyl,
wherein all alkyl residues can be linear or branched, and can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all cycloalkyl residues can be unsubstituted or substituted with one or more substituents independently selected from: —F, —Cl, —Br, —I; and C1-C3 alkyl optionally halogenated or perhalogenated; and OC1-C3 alkyl optionally halogenated or perhalogenated,
wherein all alkyl and cycloalkyl residues can be perhalogenated;
or a salt or solvate thereof; and
b) carriers, diluents and/or adjuvants suitable for administration to patients.

### Claim 16 (depends on 15)

The composition according to claim 15, wherein said adjuvants are selected from the group consisting of an immunotherapeutic agent or a vaccine adjuvant.

### Claim 17 (depends on 15)

The composition according to claim 15, further comprising a second active agent.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein said second active agent is selected from the group consisting of chemotherapeutic agents, peptide antibiotics,
alkylating agents, topoisomerase inhibitors, kinase inhibitors, inhibitors and activators of signaling pathways, retinoids, hormone signaling modulators, histone deacetylase inhibitors, other Notch enhancers not encompassed by the compounds of the present invention, Notch Signaling-activating peptides or antibodies, immune response modulating agents and anti-inflammatory agents and ACE inhibitors, beta-blockers, myostatin inhibitors, PDE-5 inhibitors and antihistamines.

### Claim 19 (depends on 18)

The composition according to claim 18, wherein said second active agent is selected from the group consisting of Cytarabin, Gemcitabine, Azathioprine, Mercaptopurine, Fluorouracil, Thioguanine, Hydroxyurea, Azacitidine, Capecitabine, Doxifluridine, Methotrexate, Cisplatin, Oxaliplatin, Carboplatin and Nedaplatin, Doxorubicin, Epirubicin, Valrubicin, Idarubicin, Daunorubicin, Sabarubicin, Pixantrone, Mitoxantrone, Actinomycin, Bleomycin, Mechlorethamine, Chlorambucil, Melphalan, Nitrosoureas, Dacarbazine, Temozolomide, Cyclophosphamide, Docetaxel, Paclitaxel, Abraxane, Cabazitaxel, Vinblastine, Vindesine, Vinorelbine, Vincristine, Irinotecan, Topotecan, Teniposide, Etoposide, Erlotinib, Lapatinib, Dasatinib, Imatinib, Afatinib, Vemurafenib, Dabrafenib, Nilotinib, Cetuximab, Trametinib, Palbociclib, Cobimetinib, Cabozantinib, Pegaptanib, Crizotinib, Olaparib, Panitumumab, Cabozantinib, Ponatinib, Regorafenib, Entrectinib, Ranibizumab, Ibrutinib, Trastuzumab, Rituximab, Alemtuzumab, Gefitinib, Bevacizumab, Lenvatinib, Bosutinib, Axitinib, Pazopanib, Everolimus, Temsirolimus, Ruxolitinib, Tofacitinib, Sorafenib, Sunitinib, Aflibercept, Bortezomib, Vandetanib; Vismodegib, Sonidegib, retinol, tretinoin, isotretinoin, alitretinoin, bexarotene, tazarotene, acitretin, adapalene, etretinate, Raloxifene, Tamoxifen, Fulvestrant, Lasofoxifene, Toremifene, Bicalutamide, Flutamide, Anastrozole, Letrozole, Exemestane, Vorinostat, Romidepsin, Panobinostat, Belinostat, Chidamide, Ingenol mebutate, Valproic acid, Resveratrol, hesperetin, chrysin, phenethyl isothiocyanate, thiocoraline, N-methylhemeanthidine chloride, imiquimod, Ipilimumab, Atezolizumab, Ofatumumab, Rituximab, Nivolumab, Pembrolizumab, Dexamethason, Betamethason, Prednisone, Prednisolone, Methylprednisolone, Triamcinolon-hexacetonid, Mometasonfuroat, Clobetasolpropionat, acetylsalicylic acid, salicylic acid and other salicylates, Diflunisal, Ibuprofen, Dexibuprofen, Naproxen, Fenoprofen, Ketoprofen, Dexketoprofen, Loxoprofen, Flurbiprofen, Oxaprozin, Indomethacin, Ketorolac, Tolmetin, Diclofenac, Etodolac, Aceclofenac, Nabumetone, Sulindac, Mefenamic acid, Meclofenamic acid, Flufenamic acid, Tolfenamic acid, Celecoxib, Parecoxib, Etoricoxib and Firocoxib.

### Claim 20 (depends on 1)

A kit comprising the compound according to claim 1 and a second active agent, wherein said compound and said second active agent are in separate dose forms which can be co-administered or administered separately.

### Claim 21

A compound selected from the group consisting of:
